FLORAL
Long-term treatment with etavopivat in people with sickle cell disease or thalassaemia https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/7822-floral-long-term-treatment-with-etavopivat-in-people-with-sickle-cell-disease-or-thalassaemia/
REDRESS (RElated haplo-DonoR haematopoietic stEm cell transplantation for adults with Severe Sickle cell disease)
The purpose of this trial is to determine whether stem cell transplant using haplo-identical related donors is safe, effective, and cost worthy in treating people with sickle cell disorder compared with the standard of care treatment. Stem cell transplant from a haplo-identical donor is not currently available on the NHS and can only be accessed […]
NIHR Rapid Service Evaluation Team (REVAL)
Evaluation of pilot hyperacute units to deliver acute sickle cell care as part of a wider programme of quality improvement (SCD)In response to recognition of avoidable deaths and failures of care for people with sickle cell, NHS England is funding a transformation programme to respond to areas of identified need and clinical risk for people […]
HIBISCUS
Exploring the use of a new drug in patients with sickle cell disease. The HIBISCUS study started at the King’s College Hospital Denmark Hill campus in June 2022 with patients attending the King’s Clinical Trials Facility for their treatment. This includes a monthly medical review, examination, blood tests and to collect a further supply of […]
Haematology Lived Experience and Outcomes (HALO)
HALO is a research study looking at the survival rates of people diagnosed with Sickle Cell Disorder or Beta Thalassemia, acute Lymphoblastic or acute Myeloid Leukaemia in childhood and the long-term effects of that diagnosis and treatment. Read more here: https://choralresearch.org.uk/sub-projects/haematology-lived-experience-and-outcomes-halo/
